TrialOncotarget2016
An assessment of the benefit-risk balance of FOLFIRINOX in metastatic pancreatic adenocarcinoma.
Julien Péron et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
7 papers cite it
this papercites it
TrialOncotarget2016
Julien Péron et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.